<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00532701</url>
  </required_header>
  <id_info>
    <org_study_id>200709014M</org_study_id>
    <nct_id>NCT00532701</nct_id>
  </id_info>
  <brief_title>Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR</brief_title>
  <official_title>Peginterferon Alfa-2a Plus Ribavirin in Patients With Genotype 2 Chronic Hepatitis C: A Randomized Study of Treatment Duration and Ribavirin Dose Stratified by Rapid Virologic Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Health, Executive Yuan, R.O.C. (Taiwan)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment with peginterferon plus daily low dose (800 mg) or weight-based ribavirin (800-1400
      mg) for 24 to 48 weeks has achieved 70-93% sustained virologic response (SVR) rates in
      patients with genotype 2 or 3 chronic hepatitis C (CHC). Recently, a large randomized study
      has shown that patients with genotype 2 or 3 CHC have comparable SVR rates for those who
      received peginterferon for 24 or 48 weeks, and who received daily low dose (800 mg) or
      standard dose (1000-1200 mg) ribavirin. Therefore, the currently recommended treatment for
      these patients is 24 weeks of peginterferon plus low dose ribavirin. Because of the high
      response rates, several studies have shown that when these patients had rapid virologic
      response (RVR), defined as undetectable hepatitis C virus (HCV) ribonucleic acid (RNA)
      levels, at week 4 of peginterferon plus weight-based ribavirin, 12-16 weeks of treatment
      could have 82-94% SVR rates. However, treatment with peginterferon plus low dose ribavirin
      for 24 weeks showed significantly higher SVR rates than that for 16 weeks (85% versus 79%) in
      these patients who achieved RVR. While studies showed concordant results in SVR rates for
      patients with genotype 3 CHC who received peginterferon plus low dose or weight-based
      ribavirin for 16 or 24 weeks, the SVR rates stratified by RVR showed great differences in
      patients with genotype 2 CHC who received such treatment. Currently, there are no studies on
      the direct comparison of low dose versus weight-based ribavirin, and of 16 to 24 weeks of
      treatment stratified by RVR for patients with genotype 2 CHC. The investigators aimed to
      conduct a randomized trial to determine the optimal ribavirin dose and treatment duration of
      peginterferon plus ribavirin for patients with genotype 2 CHC based on RVR studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment with peginterferon plus daily low dose (800 mg) or weight-based ribavirin (800-1400
      mg) for 24 to 48 weeks has achieved 70-93% sustained virologic response (SVR) rates in
      patients with genotype 2 or 3 chronic hepatitis C (CHC). Recently, a large randomized study
      has shown that patients with genotype 2 or 3 CHC have comparable SVR rates for those who
      received peginterferon for 24 or 48 weeks, and who received daily low dose (800 mg) or
      standard dose (1000-1200 mg) ribavirin. Therefore, the currently recommended treatment for
      these patients is 24 weeks of peginterferon plus low dose ribavirin. Because of the high
      response rates, several studies have shown that when these patients had rapid virologic
      response (RVR), defined as undetectable hepatitis C virus (HCV) RNA levels, at week 4 of
      peginterferon plus weight-based ribavirin, 12-16 weeks of treatment could have 82-94% SVR
      rates. However, treatment with peginterferon plus low dose ribavirin for 24 weeks showed
      significantly higher SVR rates than that for 16 weeks (85% vs. 79%) in these patients who
      achieved RVR. While studies showed concordant results in SVR rates for patients with genotype
      3 CHC who received peginterferon plus low dose or weight-based ribavirin for 16 or 24 weeks,
      the SVR rates stratified by RVR showed great differences in patients with genotype 2 CHC who
      received such treatment. Currently, there are no studies on the direct comparison of low dose
      versus weight-based ribavirin, and of 16 to 24 weeks of treatment stratified by RVR for
      patients with genotype 2 CHC. We aimed to conduct a randomized trial to determine the optimal
      ribavirin dose and treatment duration of peginterferon plus ribavirin for patients with
      genotype 2 CHC based on RVR studies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virologic response (SVR)</measure>
    <time_frame>1.5 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histologic response (HR)</measure>
    <time_frame>1.5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical response (BR)</measure>
    <time_frame>1.5</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">880</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Peg-IFN + WB RBV for 16 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weight-based ribavirin (1000-1200 mg/day) from weeks 1-16 in patients with RVR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peg-IFN + LD RBV for 16 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weight-based ribavirin (1000-1200 mg/day) from weeks 1-6, and then low dose ribavirin (800 mg/day) from weeks 6-16 in patients with RVR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peg-IFN + WB RBV for 24 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weight-based ribavirin (1000-1200 mg/day) from weeks 1-24 in patients without RVR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peg-IFN + WB RBV for 48 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weight-based ribavirin (1000-1200 mg/day) from weeks 1-48 in patients without RVR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peg-IFN + LD RBV for 24 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose ribavirin (800 mg/day) from weeks 1-24 in patients with or without RVR</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg-IFN + WB RBV for 16 weeks</intervention_name>
    <description>Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (&lt; 75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) from weeks 1-4
Rapid virologic response (RVR) at week 4 of therapy: achieved
Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (&lt; 75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) from weeks 5-16</description>
    <arm_group_label>Peg-IFN + WB RBV for 16 weeks</arm_group_label>
    <other_name>Pegasys plus Copegus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg-IFN + LD RBV for 16 weeks</intervention_name>
    <description>Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (&lt; 75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) from weeks 1-6
Rapid virologic response (RVR) at week 4 of therapy: achieved
Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 6-16</description>
    <arm_group_label>Peg-IFN + LD RBV for 16 weeks</arm_group_label>
    <other_name>Pegasys plus Copegus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg-IFN + WB RBV for 24 weeks</intervention_name>
    <description>Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (&lt; 75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) from weeks 1-4
Rapid virologic response (RVR) at week 4 of therapy: not achieved
Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-24</description>
    <arm_group_label>Peg-IFN + WB RBV for 24 weeks</arm_group_label>
    <other_name>Pegasys plus Copegus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg-IFN + WB RBV for 48 weeks</intervention_name>
    <description>Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (&lt; 75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) from weeks 1-4
Rapid virologic response (RVR) at week 4 of therapy: not achieved
Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-48</description>
    <arm_group_label>Peg-IFN + WB RBV for 48 weeks</arm_group_label>
    <other_name>Pegasys plus Copegus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg-IFN + LD RBV for 24 weeks</intervention_name>
    <description>Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 1-24
Rapid virologic response (RVR) at week 4 of therapy: both achieved and not achieved</description>
    <arm_group_label>Peg-IFN + LD RBV for 24 weeks</arm_group_label>
    <other_name>Pegasys plus Copegus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment naïve

          -  Age older than 18 years old

          -  Anti-HCV (Abbott HCV EIA 2.0, Abbott Diagnostic, Chicago, IL) positive &gt; 6 months

          -  Detectable serum quantitative HCV-RNA (Cobas Taqman HCV Monitor v2.0, Roche
             Diagnostics) with dynamic range 25 ~ 391000000 IU/ml

          -  HCV genotype 2 (Inno-LiPA HCV II, Innogenetics, Ghent, Belgium)

          -  Serum alanine aminotransferase levels above the upper limit of normal with 6 months of
             enrollment

          -  A liver biopsy consistent with the diagnosis of chronic hepatitis C

        Exclusion Criteria:

          -  Anemia (hemoglobin &lt; 13 grams per deciliter for men and &lt; 12 grams per deciliter for
             women)

          -  Neutropenia (neutrophil count &lt; 1,500 per cubic milliliter)

          -  Thrombocytopenia (platelets &lt; 90,000 per cubic milliliter)

          -  Co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

          -  Chronic alcohol abuse (daily consumption &gt; 20 grams per day)

          -  Decompensated liver disease (Child-Pugh class B or C)

          -  Serum creatinine level more than 1.5 times the upper limit of normal

          -  Autoimmune liver disease

          -  Neoplastic disease

          -  An organ transplant

          -  Immunosuppressive therapy

          -  Poorly controlled autoimmune diseases, pulmonary diseases, cardiac diseases,
             psychiatric diseases, neurological diseases, diabetes mellitus

          -  Evidence of drug abuse

          -  Unwilling to use contraception

          -  Unwilling to sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia-Horng Kao, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ding-Shinn Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ming-Yang Lai, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pei-Jer Chen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chun-Jen Liu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chen-Hua Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shih-Jer Hsu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital, Yun-Lin Branch</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chih-Lin Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei City Hospital, Ren-Ai Branch</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheng-Chao Liang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Far Eastern Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ching-Sheng Hsu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Buddhist Xindian Tzu Chi General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheng-Shun Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chia-Chi Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Buddhist Xindian Tzu Chi General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tai-Chung Tseng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Buddhist Xindian Tzu Chi General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ming-Lung Yu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wan-Long Chuang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chia-Yen Dai, MD, Ms</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Municipal Hsiao-Kang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jee-Fu Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Municipal Hsiao-Kang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chang-Fu Chiu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Paochien Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital, Yun-Lin Branch</name>
      <address>
        <city>Douliou</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Municipal Hsiao-Kang Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paochien Hospital</name>
      <address>
        <city>Pingtung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buddhist Xindian Tzu Chi General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ren-Ai Branch, Taipei Municipal Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001 Sep 22;358(9286):958-65.</citation>
    <PMID>11583749</PMID>
  </reference>
  <reference>
    <citation>Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26;347(13):975-82.</citation>
    <PMID>12324553</PMID>
  </reference>
  <reference>
    <citation>Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004 Mar 2;140(5):346-55.</citation>
    <PMID>14996676</PMID>
  </reference>
  <reference>
    <citation>Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, Sarrazin C, Harvey J, Brass C, Albrecht J. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol. 2004 Jun;40(6):993-9. Erratum in: J Hepatol. 2005 Mar;42(3):434.</citation>
    <PMID>15158341</PMID>
  </reference>
  <reference>
    <citation>Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S; ACCELERATE Investigators. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007 Jul 12;357(2):124-34.</citation>
    <PMID>17625124</PMID>
  </reference>
  <reference>
    <citation>Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004 Apr;39(4):1147-71. Erratum in: Hepatology. 2004 Jul;40(1):269.</citation>
    <PMID>15057920</PMID>
  </reference>
  <reference>
    <citation>Dalgard O, Bjøro K, Hellum KB, Myrvang B, Ritland S, Skaug K, Raknerud N, Bell H. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology. 2004 Dec;40(6):1260-5.</citation>
    <PMID>15558712</PMID>
  </reference>
  <reference>
    <citation>von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, Bergk A, Bernsmeier C, Häussinger D, Herrmann E, Zeuzem S. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005 Aug;129(2):522-7.</citation>
    <PMID>16083709</PMID>
  </reference>
  <reference>
    <citation>Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005 Jun 23;352(25):2609-17.</citation>
    <PMID>15972867</PMID>
  </reference>
  <reference>
    <citation>Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, Chiu CF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut. 2007 Apr;56(4):553-9. Epub 2006 Sep 6.</citation>
    <PMID>16956917</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2007</study_first_submitted>
  <study_first_submitted_qc>September 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2007</study_first_posted>
  <last_update_submitted>June 3, 2014</last_update_submitted>
  <last_update_submitted_qc>June 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>Genotype</keyword>
  <keyword>Interferon</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Genotype 2</keyword>
  <keyword>Peginterferon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

